SHERBROOKE, Quebec & VIENNA, Austria—Pharmaceutical company Cyclenium Pharma Inc. has inked a research agreement with Haplogen GmbH to discover novel pharmaceutical candidates in multiple disease areas. The two companies will focus on certain antiviral Haplogen targets initially, and will phase-in additional targets in other therapeutic indications as research progresses. Haplogen brings with it unique haploid genetics technology and experience in host target identification, validation and screening, while Cyclenium can provide its CMRT Technology-derived QUEST Library and hit-to-lead optimization expertise.